News
10-02-2017, 12:40 PM
The U.S. Food and Drug Administration (FDA) has approved a new drug Verzenio (abemaciclib) for the treatment of advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
More... (https://www.news-medical.net/news/20171002/FDA-approves-Verzenio-for-advanced-metastatic-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20171002/FDA-approves-Verzenio-for-advanced-metastatic-breast-cancer.aspx)